Gastroenterology Review
eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2026
vol. 21
 
Share:
Send email
Share:
Review paper

A comprehensive review of usefulness of sodium butyrate for the management of inflammatory bowel disease: from molecular mechanisms to clinical application

Katarzyna Karłowicz
1
,
Konrad Lewandowski
1
,
Edyta Tulewicz-Marti
1
,
Grażyna Rydzewska
1, 2

  1. Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
  2. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Gastroenterology Rev 2026; 21 (1): 29–37
DOI: https://doi.org/10.5114/pg.2026.159719
Online publish date: 2026/02/25
Article file
- A comprehensive review.pdf  [0.35 MB]
Get citation
 
PlumX metrics:
 
1. Łodyga M, Eder P, Gawron-Kiszka M, et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2021; 16: 257-96.
2. Eder P, Łodyga M, Gawron-Kiszka M, et al. Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2023;18: 1-42.
3. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022; 16: 2-17.
4. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020; 14: 4-22.
5. Atlas kliniczno-patologiczny nieswoistych chorób zapalnych jelit. Wejman J, Bartnik W, editors. Termedia Poznan 2011.
6. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-9.
7. Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019; 2019: 7247238.
8. Holleran G, Lopetuso L, Ianiro G, et al. Gut microbiota and inflammatory bowel disease: so far so gut! Minerva Gastroenterol Dietol 2017; 63: 373-84.
9. Qiu P, Ishimoto T, Fu L, et al. The gut microbiota in inflammatory bowel disease. Front Cell Infect Microbiol 2022; 12: 733992.
10. Federici S, Kredo-Russo S, Valdés-Mas R, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 2022; 185: 2879-98.e24.
11. Kotunia A, Pietrzak P, Guilloteau P, et al. Butyric acid in gastrointestinal tract. Gastroenterology Rev 2010; 5: 117-22.
12. Banasiewicz T, Borycka-Kiciak K, Dobrowolska-Zachwieja A, et al. Clinical aspects of sodium butyrate application in dietary treatment of bowel diseases. Gastroenterology Rev 2010; 5: 329-34.
13. Skrzydło-Radomańska B. Application of butyric acid preparations in clinical practice. Lekarz POZ 2019; 5: 67-74.
14. Hamer HM, Jonkers D,  Venema K, et al. The role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-19.
15. Scheppach W, Bartram P, Richter A, et al. Effect of short-chain fatty acids on the human colonic mucosa in vitro. J Parent Enteral Nutr 1992; 16: 43-8.
16. Singh N, Gurav A, Sivaprakasam S, Brady E, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014; 40: 128-39.
17. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-50.
18. Arpaia N, Campbell C, Fan X, Dikiy S, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-5.
19. Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1b, and nuclear factor kB in trinitrobenzene sulphonic acid–induced colitis in rats. Postgrad Med J 2006; 82: 130-5.
20. Jobin C, Balfour Sartor R. The IkB/NF-kB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451-62.
21. Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NF-kB inhibition: implications for Crohn’s disease. Gut 2000; 47: 397-403.
22. Couto MR, Gonçalves P, Magro F, et al. Microbiota-derived butyrate regulates intestinal inflammation: focus on inflammatory bowel disease. Pharmacol Res 2020; 159: 104947.
23. Czajkowska A, Szponar B. Short-chain fatty acids (SCFA), the products of gut bacteria metabolism and their role in the host. Postęp Higieny Med Dośw 2018; 72: 131-42.
24. Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived SCFAs and epithelial HIF augments barrier function. Cell Host Microbe 2015; 17: 662-71.
25. Recharla N, Geesala R, Shi XZ. Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review. Nutrients 2023; 15: 2275.
26. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol 2017; 19: 29-41.
27. Rivière A, Selak M, Lantin D, et al. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 2016; 7: 979.
28. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-8.
29. Mortensen FV, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 1996; 216: 132-48.
30. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17: 1519-28.
31. Andoh A, Bamba T, Sasaki M. Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. J Parenter Enter Nutr 1999; 23 (5 Suppl): S70-3.
32. Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005; 128: 1996-2008.
33. Tarrerias AL, Millecamps M, Alloui A, et al. Short-chain fatty acid enemas fail to decrease colonic hypersensitivity and inflammation in TNBS-induced colonic inflammation in rats. Pain 2002; 100: 91-7.
34. Vanhoutvin SA, Troost FJ, Kilkens TO, et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952-76.
35. Bajka BH, Clarke JM, Topping DL, et al. Butyrylated starch increases large bowel butyrate levels and lowers colonic smooth muscle contractility in rats. Nutr Res 2010; 30: 427-34.
36. Bultman SJ. Interplay between diet, gut microbiota, epigenetic regulation, and colorectal cancer. Nat Rev Cancer 2017; 17: 652-69.
37. McNabney SM, Henagan TM. Short-chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients 2017; 9: 1348.
38. Wong JMW, de Souza R, Kendall CWC, et al. Colonic health: fermentation and short-chain fatty acids. Cancer Letters 2005; 221: 133-47.
39. Xi Y, Jing Z, Wei W, et al. Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network. BMC Cancer 2021; 21: 127.
40. Tang Y, Chen Y, Jiang H, et al. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int J Cancer 2011; 128: 847-56.
41. Venegas DP, Marjorie K, Landskron G, et al. Short-chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontn Immunol 2019; 10: 277.
42. Banasiewicz T, Borycka-Kiciak K, Kiciak A, et al. Kwas masłowy w zapaleniach jelit. Gastroenterology Rev 2010; 5: 251-7.
43. Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis: preliminary report. Dig Dis Sci 1991; 36: 185-7.
44. Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103: 51-6.
45. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994; 89: 179-83.
46. Vernia P, Cittadini M, Caprilli R, et al. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995; 40: 305-7.
47. Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 309-13.
48. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, et al. Treatment of refractory distal ulcerative colitis with short-chain fatty acid enemas. Am J Gastroenterol 1996; 91: 731-4.
49. Scheppach W, German Austrian SCFA Study Group. Treatment of distal ulcerative colitis with short-chain fatty acid enemas: a placebo-controlled trial. Dig Dis Sci 1996; 41: 2254-9.
50. Steinhart AH, Hiruki T, Brzezinski A, et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996; 10: 729-36.
51. Breuer RI, Soergel KH, Lashner BA, et al. Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo-controlled trial. Gut 1997; 40: 485-91.
52. Lührs H, Gerke T, Müller JG, et al. Butyrate inhibits NF-kB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37: 458-66.
53. Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Investig 2003; 33: 244-8.
54. Vernia P, Monteleone G, Grandinetti G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000; 45: 976-81.
55. Assisi RF, GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-to-moderate activity: results of a multicentre pilot study. Minerva Gastroenterol Dietol 2008; 54: 231-8.
56. Vernero M, De Blasio F, Ribaldone DG, et al. The usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study. J Clin Med 2020; 9: 3941.
57. Kaczmarczyk O, Dąbek-Drobny A, Woźniakiewicz M, et al. Altered fecal short-chain fatty acid profile as a potential marker of disease activity in patients with ulcerative colitis and Crohn’s disease: a pilot study. Pol Arch Intern Med 2022; 132: 16254.
58. Firoozi D, Masoumi SJ, Mohammad-Kazem Hosseini Asl S, et al. Effects of short-chain fatty acid–butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. Lipids Health Dis 2024; 23: 216.
59. Karlowicz K, Lewandowski K, Kaniewska M, et al. Efficacy of microencapsulated sodium butyrate as add-on therapy in inducing remission in patients with mild-to-moderate ulcerative colitis: results from a multicenter, double-blind, randomized, placebo-controlled study. Med Sci Monitor 2025; 31: e948912.
60. Karłowicz K, Lewandowski K, Domżał-Magrowska D, et al. Fecal butyric acid as a predictive biomarker of endoscopic remission in inflammatory bowel disease: a multicenter prospective study. Gastroenterology Rev 2025; 20: 443-8.
61. Di Sabatino A, Morera R, Ciccocioppo R, et al. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther 2005; 22: 789-94.
62. Facchin S, Vitulo N, Calgaro M, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil 2020; 32: e13914.
63. Pietrzak A, Banasiuk M, Szczepanik M, et al. Sodium butyrate effectiveness in children and adolescents with newly diagnosed inflammatory bowel diseases: a randomized placebo-controlled multicenter trial. Nutrients 2022; 14: 3283.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.